Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million.

Business Highlights

  • Idenix announced today that it had successfully completed a proof-of-concept study of its lead HCV antiviral development program, IDX184, a novel once-daily liver-targeted nucleotide prodrug. This double-blind, placebo-controlled, monotherapy, dose-escalation study in HCV genotype-1-infected patients evaluated the safety and antiviral activity of IDX184. For more information on the results of this study, please see the related press release issued today by Idenix.
  • The company continued to advance its two preclinical HCV antiviral programs. Idenix is finalizing IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory filings. The company has synthesized the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic toxicology studies in two species to support regulatory applications.
  • Finally, during the quarter, Idenix streamlined operations with the closure of its screening facility in Cagliari, Italy. This activity is now being performed at the company's laboratory in Cambridge, Massachusetts. As a result, Idenix reduced its workforce by 18 employees and incurred a restructuring charge in the quarter of $1.5 million.

"Our focus this year has been on the advancement of our HCV discov
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... 30, 2014 Each year in ... require medical attention. In the military, burn injury ... to battlefield medical care. More than 800 service ... Burn wounds heal slowly, remain inflamed and often ... physically debilitating and functionally damaging. While developments in ...
(Date:9/29/2014)... BEACH, Va. , Sept. 29, 2014 /PRNewswire-USNewswire/ ... from the fields of cartilage repair, regeneration, allograft ... attendees from around the world gathered to discuss ... LifeNet Health Institute of Regenerative Medicine symposium, ... Direction . Topics included Orthopedic Biosurgery, Minced Juvenile ...
Breaking Biology Technology:Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Organization Exceeds Expectations, MEMPHIS, Tenn., Nov. ... exclusively focused on oncology, announced today that ... as the company continues,to experience banner growth. ... to consistently exceed client expectations, and we ...
... N.J., Nov. 10 Aton Pharma, Inc., ... a recent,survey of ophthalmologists regarding issues in ... dry eye. Aton provides the dry eye ... sustained release prescription insert that helps to ...
... 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company focused ... in China,today announced that it has filed with ... approval of NuLeusin for the treatment of late,stage ... expected to,be the only treatment of this kind ...
Cached Biology Technology:ACORN CRO Continues Growth in Strong Third Quarter 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 53SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:9/29/2014)... research team says recently identified radiation detection properties of ... doors for homeland security and medical advances. , In ... issue of Optics Letters , UT Arlington Physics ... method to fabricate transparent nanoscintillators by heating nanoparticles composed ... is formed. A scintillator refers to a material ...
(Date:9/29/2014)... has presented Dr. Cristin Samper, president and CEO ... Order of San Carlos. , The Order of ... military officers who have made outstanding contributions to ... relations. , An international authority on conservation biology ... the Colombian Residence in New York to receive ...
(Date:9/29/2014)... annual Advocacy Awards will ... advancing medical progress to improve the health and ... take place on Wednesday, March 11, 2015, at ... , The 2015 Advocacy Award winners are ABC,s ... founder of the Milken Institute and FasterCures; Dr. ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4
... warming despite emitting small amounts of an important greenhouse gas, ... of Edinburgh suggests that plant leaves account for less than ... is considered to be about 25 times more effective than ... a previous scientific study which had suggested that plants were ...
... WASHINGTON, April 29, 2010 The American Chemical ... has awarded its 2010 research grant to Scottish ... strides in expanding green chemistry and engineering practices ... the one-year $150,000-grant to further his study of ...
... Thomas Miller , an internationally recognized expert at ... and genetics, has been chosen by the U.S. Department ... Fellowship . Miller is one of only ten ... applicants undergo a rigorous selection process, are highly accomplished ...
Cached Biology News:ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist 2US Department of State names UCR entomologist a Jefferson Science Fellow 2US Department of State names UCR entomologist a Jefferson Science Fellow 3